Introduction
The deficiency of glucose-6-phosphatase (G6Pase) underlies glycogen storage disease type Ia (GSD-Ia, also known as von Gierke disease; MIM 232200), an autosomal recessive disorder of metabolism associated with life-threatening hypoglycemia and growth retardation. Patients with GSD-Ia typically present with hypoglycemia and seizures at a few months of age, and develop long-term complications of growth failure, renal dysfunction, gout, osteoporosis and hepatic adenomas that can degenerate to hepatocellular carcinoma. 1 Pulmonary hypertension and early-onset atherosclerosis have been reported. 2, 3 Thus, GSD-Ia is a severe, multi system disorder that results in significant morbidity and mortality.
The phenotype of a G6Pase knockout (G6Pase-KO) mouse model closely mimics human GSD-Ia. 4 Limitations of the G6Pase-KO mouse model include poor viability and the absence of lactic acidosis, which is prominent in GSD-Ia. Only 15% of affected mice survived weaning at 21 days, despite injection with 10% glucose every 8 h. 5 Neonatal administration of an adenovirus vector encoding G6Pase improved survival markedly, either by itself or in combination with an adeno-associated virus (AAV) vector; however, administration of an AAV serotype 2 (AAV2) vector encoding unregulated G6Pase did not prolong survival. 5, 6 Administration of an AAV2 vector encoding canine glucose-6-phosphatase (cG6Pase) corrected hypercholesterolemia and prolonged survival, compared to untreated, affected GSD-Ia dogs, despite the persistence of intermittent hypoglycemia. 7 Glucose-6-phosphatase is a key regulatory enzyme in producing glucose from glycogen. Regulation of G6Pase at the level of transcription occurs in response to glucose and insulin levels. Overexpression of G6Pase is associated with diabetes mellitus in humans, and caused hyperglycemia in rats. 8 Therefore, excessive G6Pase expression would be harmful in the setting of gene therapy for GSD-Ia. The presence of only 10% of normal G6Pase levels would be therapeutic in GSD-Ia, as a patient with 8% G6Pase activity had no hypoglycemia. 9 Given that AAV vectors pseudotyped as serotype 8 (AAV2/8) transduce greater than 30% of hepatocytes, achieving at least 10% of normal G6Pase activity in the liver with AAV2/8 vectors is feasible. 10 ,11 AAV2/8 vectors delivered genes to the liver approximately 100-fold more efficiently than traditional AAV2/2 vectors. 10, 12 Indeed, the vast majority of hepatocytes could be transduced by a single administration of an AAV2/8 vector in adult mice. 10, 11 The high efficiency of AAV2/8 vector could stem from the properties of a unique, as yet unidentified receptor for AAV8 in the liver. The efficacy of an AAV2/8 vector was evaluated in GSD-Ia mice by investigating the correction of biochemical abnormalities and prolongation of survival.
Results
Prolonged survival and biochemical correction with an AAV2/8 vector encoding glucose-6-phosphatase in glycogen storage disease type Ia mice An AAV vector containing the cG6Pase promoter driving G6Pase expression (AAV-cG6PGH) was pseudotyped as AAV2/8, and administered intravenously to 2-week-old affected G6Pase-KO mice (n ¼ 9; 1 Â 10 12 DNAse-resistant vector particles/mouse, equivalent to 2 Â 10 14 particles/ kg). Seven of nine affected mice survived to at least 7 months old (m.o) following AAV vector administration, in contrast to untreated affected mice that did not survive past 2-3 weeks old (w.o.) (Figure 1a ; log-rank test Po0.001). Untreated, affected mice initially weighed 50% less than unaffected littermates (Po0.001 at 2 weeks of age), but growth normalized by 4 w.o. following gene therapy (Figure 1b-c) .
Treated, affected mice had increased blood glucose after 2 h of fasting (81730 mg/dl) at 1 m.o., in contrast to two w.o. untreated, affected G6Pase-KO mice that were very hypoglycemic (31719 mg/dl; Po0.005) (Figure 2a ). Blood glucose during fasting remained lower in treated, affected mice than in normal mice at 4 and 6 m.o. (Figure  2a , Po0.05). To determine whether residual hypoglycemia resulted from low activity of the G6Pase promoter, an AAV2/8 vector containing the ubiquitously active CB (cytomegalovirus immediate early enhancer/chicken beta-actin promoter) promoter/enhancer to drive G6Pase expression was administered to a group of affected G6Pase-KO mice (n ¼ 3; 3 Â 10 11 particles, equivalent to 6 Â 10 13 particles/kg). Despite the documented activity of the CB promoter/enhancer in mouse liver, blood glucose during fasting was only partially corrected at 4 w.o. (to 60717 mg/dl). 12, 13 Thus, high numbers of AAV2/8 vector particles were required to partially correct hypoglycemia during fasting in infant GSD-Ia mice, despite substitution of a well-characterized, high-activity promoter/enhancer for the G6Pase promoter.
Complete correction of blood cholesterol was achieved in affected mice following AAV vector administration (Po0.001), and remained equivalent for treated, affected mice and wild-type mice for the duration of the experiment (Figure 2b ). Blood glucose in absence of fasting was similar for affected, treated mice and wildtype mice at 7 m.o.; moreover, triglycerides were somewhat reduced in plasma for treated, affected mice in comparison to untreated, affected mice (Table 1) . Importantly, G6Pase activity was significantly increased in the liver of affected mice following AAV2/8 vector administration, and was sustained at approximately 25% of the normal level at 7 m.o. (Table 1) .
Early correction of hypoglycemia and accompanying biochemical abnormalities would prolong survival in animal models for GSD-Ia, and therefore the short-term efficacy of AAV vector-mediated gene therapy was evaluated in G6Pase-KO mice. Three affected mice were monitored following vector administration at 2 weeks of age by urine organic acid analysis. The marked lactic aciduria observed for untreated, affected mice was (Figure 3d ). In the kidney, G6Pase activity was elevated and glycogen content was reduced at 1 m.o., albeit not significantly so; however, G6Pase disappeared and glycogen content increased to high levels by 7 m.o. (Table 1 ). Glucose-6-phosphatase expression persisted at lower levels to 10 m.o. in the liver as detected by RT-PCR (Figure 3e , lanes 4-9); however, G6Pase expression declined to almost undetectable levels at 7 and 10 m.o. in the kidney ( Figure  3e , lanes [11] [12] [13] [14] [15] [16] . No signal for vector DNA and RNA was present for phosphate-buffered saline (PBS)-treated mice (Figure 3c -e, PBS) and no signal for b-actin was present for negative control polymerase chain reactions reactions (PCR) (Figure 3c -e, lane 2), indicating that samples and reagents were not contaminated with exogenous nucleic acids. In summary, PCR detection of vector DNA and RNA reflected the loss of vector genomes in kidney by 7 m.o., consistent with the absence of G6Pase expression in the kidney (Table 1) .
Histological analysis of the liver and kidney revealed partial histomorphological correction during the first 6 months following vector administration ( Figure 4axii and axv) ; moreover, the marked accumulation of glycogen in the kidney was consistent with the lack of G6Pase expression in that tissue (Figure 4axviii and axx).
Correction of GSD-
A cellular immune response does not eliminate glucose-6-phosphatase expression in glycogen storage disease type Ia mice
Immune responses to introduced G6Pase were evaluated following vector administration, because G6Pase represented a neoantigen in affected G6Pase-KO mice. Lymphocytic infiltrates were not prominent in treated, affected mouse liver at 1 m.o., although extramedullary hematopoeisis was present (Figure 4bi ). Untreated, affected mice had only extramedullary hematopoeisis in the liver, not lymphocytic infiltrates, indicating that infiltrates were associated with vector administration (not shown). Infrequent, focal lymphocytic infiltrations were present at 7 m.o. in affected mice, consistent with an inflammatory response to the AAV vector in the liver ( Figure 4bii ) and kidney ( Figure 4biii ). Much less prominent lymphocytic foci were present in agematched, unaffected 7 m.o. mouse livers in response to AAV vector administration (not shown). Immunodetection of CD4+ lymphocytes in the liver at 4 w.o. suggested the presence of an immune response to vector administration (Figure 4ci ), and both CD4+ and CD8+ lymphocytic infiltrates were detected at 7 m.o. in the liver (Figure 4cii-iii) . Only CD4+ lymphocytes were detected in the kidney at 7 m.o., not CD8+ lymphocytes ( Figure  4civ ). Unaffected mice had no detectable CD4+ or CD8+ lymphocytes at 7 m.o., indicating that the presence of lymphocytic infiltrates in treated mice was related to vector administration (n ¼ 2, not shown). The presence of lymphocytic infiltrates could not be correlated with agematched, affected G6Pase-KO mice owing to the lack of survival of affected mice in absence of gene therapy; however, the apparent immune response to G6Pase did not eliminate transgene expression as late as 10 m.o. in the liver (Table 1 and Figure 3e ).
Discussion
The G6Pase-KO mouse model presents a uniquely challenging model for the development of gene therapy owing to very high, early mortality, because affected mice cannot be sustained past approximately 2 weeks of age with glucose supplementation alone. 5 The efficacy of G6Pase expression with the AAV2/8 vector containing an endogenous cG6Pase promoter was established in G6Pase-KO mice by prolonged survival, correction of growth retardation, partial correction of fasting hypoglycemia and G6Pase deficiency and normalization of blood cholesterol. Although the cG6Pase promoter has only been characterized by sequence comparisons and not by in vitro analyses, it drove G6Pase expression with efficacy similar to that of the well-described CB promoter/ enhancer.
14 A recent report indicated that an AAV2/8 vector containing a ubiquitously active promoter to drive G6Pase expression did not promote long-term survival in G6Pase-KO mice following neonatal administration; it is unclear whether the difference in promoter or the age of administration explains the higher level of efficacy achieved here. 13 Glucose-6-phosphatase expression in the liver was associated with the correction of both GAPDH overexpression and lactic aciduria, which reflected the normalization of glycolysis in the liver. Partial correction of persistent hypoglycemia, the primary abnormality in GSD-Ia, by expression of G6Pase in the liver alone improved the growth and survival of GSD-Ia mice. Therefore, a clinical trial of gene therapy involving GSD-I patients could monitor dramatic end points such as residual hypoglycemia, correction of biochemical abnormalities and accelerated growth. 1 Unlike a previous gene therapy experiment involving neonatal administration of both an adenovirus and AAV2/2 vector or an AAV2/1 vector alone, administration of this AAV2/8 vector did not achieve significant G6Pase expression in the kidney. 6, 13 Through neonatal, then repeated, administration of an AAV2/1 vector encoding murine G6Pase, partial correction of kidney G6Pase deficiency was achieved in GSD-Ia mice; nonetheless, glomerulosclerosis occurred after 49 weeks of age in treated GSD-Ia mice. 13 Thus, gene therapy has had limited impact upon kidney involvement in GSD-Ia mice. Liver G6Pase expression alone might be sufficient to improve the outcome of GSD-Ia patients, as evidenced by the experience with liver transplantation. Liver transplantation previously corrected biochemical abnormalities and enhanced linear growth velocity without correcting G6Pase deficiency in the kidneys, although the potential of liver correction for improving kidney function in GSD-Ia remains unclear. Liver transplantation has been reported in 10 patients with GSD-Ia, and hypoglycemia and other abnormal blood chemistries resolved in all patients following liver transplant. [15] [16] [17] [18] [19] [20] Four patients had increased growth velocity following transplantation. 15, 16, 19 Currently, it is unclear whether liver transplantation will prevent renal complications. 19, 20 Better metabolic control can prevent kidney enlargement, and even improve renal function in some patients. 21, 22 Presumed absence of renal complications was reported in one patient, in whom no kidney enlargement was present 9 years after transplant. 17 Two other patients had improved renal function, whereas a third had renal failure with focal glomerulosclerosis (typical for advanced GSD-Ia) following liver transplantation. 19 Increased GAPDH in affected GSD-Ia mice may be involved in non-enzymatic moonlighting activities such as induction of apoptosis and transcriptional regulation, thereby playing major role in pathogenesis. [23] [24] [25] [26] In a study of genomic alterations in GSD-Ia, we found that GAPDH expression was significantly elevated among other genes related to the control of apoptosis and transcriptional regulation. 27 Downregulation of GAPDH RNA by the correction of G6Pase deficiency could reflect a more global correction of apoptosis and cell cycle control, currently associated with the reduction of hepatocyte vacuolation following AAV vector administration. It is possible that correction of G6Pase deficiency and cell survival in the liver would reduce the risk for hepatocellular cancer in GSD-Ia. 28 Affected G6Pase-KO mice receive therapy during infancy and grow four-to five-fold in weight subsequently. Given the hyperplasia of tissues such as the liver accompanying rapid growth of young mice, the loss of vector genome DNA could be related to cell division and the accompanying reduction of episomal AAV vector Correction of GSD-Ia with an AAV2/8 vector DD Koeberl et al DNA. Analyses of AAV vector genomes in the liver previously revealed that the great majority of AAV vector DNA remains episomal, but chromosomal integration was enhanced by protein kinase C deficiency. 11, 29 Consistent with these studies, single-stranded vector genomes declined rapidly, whereas double-stranded vector genomes decreased approximately fourfold during the 6 months following vector administration. The presence of moderate CD8+ lymphocytic infiltrates in the liver of vector-treated GSD-Ia mice suggested a vector-related immune response as was observed for an AAV2/8 vector containing a ubiquitously active promoter (but not for a liver-specific promoter) in acid a-glucosidase knockout mice. 30 The possibility of an AAV capsid-related immune response cannot be excluded by the current data; however, immune responses to AAV2/8 vectors have typically been directed against the transgene and could be abrogated by liver-specific expression. 30 The gradual loss of double-stranded AAV2/8 vector genomes observed here and previously in the liver of normal mice, which was increased compared to other AAV serotypes, was not accompanied by the sharp decrease in transgene expression associated with a vigorous cellular immune response. 28, 31, 32 If AAV vector-mediated G6Pase expression gradually wanes following treatment of infants with GSD-Ia, these patients subsequently could receive a 'booster' AAV vector cross-packaged as an alternative AAV serotype because of absence of cross-neutralization by antibodies against different serotypes.
10,33-35
Liver-targeted gene therapy has great potential in GSD-Ia, because of the demonstrated efficacy of G6Pase replacement by liver transplantation. 20 Liver transplantation has generally been reserved for very severely affected patients who are resistant to standard therapy, owing to the unavailability of donor livers, the risk of graft rejection and the need for ongoing immunosuppression following transplantation. 1 An alternative therapy such as gene therapy could alleviate some of the long-term complications of GSD-I such as growth failure and renal failure, or even hepatocellular carcinoma which is increasingly prevalent in this patient population. 1, 28, 36 The efficacy of AAV vector-mediated G6Pase expression initiated during mid-infancy is highly relevant to GSD-Ia patients, for whom the diagnosis is typically established at several months of age.
Materials and methods

Preparation of adeno-associated virus vectors
The 1.6 kbp promoter region from the cG6Pase gene was cloned by PCR of the 5 0 sequences of the cG6Pase gene (GenBank accession number U91844) from a canine genomic library.
14 It contained a consensus sequence for a TATA-box located at position À39 and a consensus sequence for a CCAAT boxes located at position -116, and a number of sites with sequence homology to putative binding sites for liver-enriched transcription factors. An XbaI to KpnI fragment from position À1372-11 of the cG6Pase promoter sequence was isolated and ligated with the KpnI to XbaI fragment from pAAVCcG6PGH. 7 The resulting AAV vector plasmid, pAAVcG6PpA, contained the cG6Pase promoter to drive a cG6Pase cDNA, followed by a human growth hormone polyadenylation signal, and flanked by the AAV2 TR sequences. The vector plasmid pAAV-CBcG6PpA contains the CB promoter/enhancer to drive G6Pase expression, instead of the cG6Pase promoter. The AAV vector is pseudotyped with AAV8 capsid proteins as described; briefly, 293 cells were transfected with the AAV vector plasmid, the AAV packaging plasmid p5E18-VD 2/8 (courtesy of Dr James M Wilson, University of Pennsylvania, Philadelphia, PA, USA), and pAdHelper (Stratagene, La Jolla, CA, USA). 10 Cell lysate was harvested 48 h following infection and freeze-thawed three times, and isolated by sucrose cushion pelleting followed by two cesium chloride gradient centrifugation steps. Adeno-associated virus stocks were dialyzed against three changes of Hanks buffer, and aliquots were stored at À801C. The number of vector DNA containing particles was determined by DNase I digestion, DNA extraction and Southern blot analysis. All viral vector stocks were handled according to the Biohazard Safety Level 2 guidelines published by the National Institutes of Health (NIH).
Breeding and detection of affected glucose-6-phosphatase knockout mice Carrier G6Pase-KO mice were housed in the Duke Vivarium and bred to produce homozygous, affected G6Pase-KO offspring. Mice were screened at 4 days of age, and those weighing 43 g were killed. Of the offspring not weighing 43 g at 4 days of age, B50% were affected. Affected genotype was confirmed by PCR analysis of tail DNA with primers within and flanking the neo gene insertion in the G6Pase gene as described; however, primers for amplifying murine G6Pase exon 3 were changed to the following: forward (5 0 -GAAGT CCCTCTGGCCATG-3 0 ) and reverse (5 0 -CCGGAATCCA TACGTTGG-3 0 ). 4 In vivo administration of adeno-associated virus vector stocks AAV-cG6PGH, pseudotyped as AAV2/8, was administered intravenously (via the retroorbital sinus) to 2-weekold affected G6Pase-KO mice (n ¼ 9). At the indicated time points post injection, plasma or tissue samples were obtained and processed as described below. All animal procedures were carried out in accordance with the Duke University Institutional Animal Care and Use Committee-approved guidelines.
Survival analysis
Reported P-values are two-tailed and were derived from non-parametric methods for continuous variables. Survival analysis included production of Kaplan-Meier curve and P-values presented were from log-rank test.
Enzyme and biochemical analysis
Enzyme analysis was performed as described. 7, 37 Briefly, liver was flash-frozen and stored at À701C. Specific G6Pase activity was measured by using G6P as substrate after subtraction of nonspecific phosphatase activity as estimated by b-glycerophosphate. Glycogen content was assayed as described. 7 Serum glucose and cholesterol was analyzed with a Kodak Biolyzer (Kodak, Rochester, NY, USA).
Urine organic acids were analyzed by capillary gas chromatography-mass spectrometry as ethoxime-triCorrection of GSD-Ia with an AAV2/8 vector DD Koeberl et al methylsilyl derivatives using a modification of a standard procedure. 38 A fixed amount of 13 C 3 -labeled lactic and pyruvic acids (obtained from Cambridge Isotope Laboratories, Andover, MA, USA) was added to a fixed volume (25 ml) of urine as internal standards before extraction. Full scan GC/MS data were acquired over the mass range of 50-600 at a rate of 0.5 s/scan. Lactic and pyruvic acids were quantified by generating ion current chromatograms corresponding to endogenous and labeled lactic and pyruvic acids from the full scan data, and comparing the ratios of the signals to a standard curve (signal ratio vs concentration of added acid).
A two-tailed homoscedastic Student's t-test was used to determine significant differences in G6Pase levels, glycogen content and other measurements between G6Pase-KO mice with or without administration of the vector encoding G6Pase.
Quantitation of vector DNA and detection of vector RNA by reverse transcription-polymerase chain reaction Genomic DNA was extracted from GSD Ia mice livers or kidneys. The signal for a of liver DNA Southern blot was quantitated based on the integrated density of each sample with program of ImageJ (Image Processing and Analysis in Java) downloaded from NIH website. The number of AAV vector genomes/liver cell for each sample was calculated from standard curve. Semiquantitative PCR was performed in a 50-ml reaction containing 500 ng of DNA from each sample, 2.5 units of Taq DNA polymerase with 1 Â PCR buffer (Qiagen, Valencia, CA, USA) and 150 ng each of the sense and antisense primers. Gene-specific primers for cG6Pase cDNA primers (sense 5 0 -TTCCCATCTGGTTCCATCTG CGT-3 0 , nucleotide 205-227, and antisense 5 0 -GGATATT CAAGCACCGAAATCTG-3 0 , nucleotide 503-525, GenBank U91844), and for mouse b-actin (sense 5 0 -AGAGGG AAATCGTGCGTGAC-3 0 and antisense 5 0 -CAATAGT GATGACCTGGCCGT-3 0 ) were used for each reaction. 39 Samples were denatured at 941C for 3 min, then followed by 32 cycles (27 cycles for b-actin, internal control) of 941C for 30 s, 581C for 30 s and 721C for 45 s. Plasmid DNA corresponding to 0.001 copy to 10 copies of cG6Pase gene (in 500 ng genomic DNA) was mixed with 500 ng of genomic DNA from control (PBS-treated) GSDIa mouse as the standards for semiquantitative assay. The reaction was terminated with a 10-min extension at 721C. Aliquots of 20 ml of each PCR reaction were electrophoretically separated on 1.2% agarose gel with ethidium bromide and photographed. Total RNA was extracted from mouse tissues using RNeasy Mini Kit (Qiagen). Three micrograms of total RNA was reverse transcribed with 300 units of M-MLV reverse transcriptase (Life Technologies Inc., Gaithersburg, MD, USA) and 300 ng of random hexamer primers in a 40-ml reaction. Four microliters of of cDNA was subjected to PCR as described above.
Glyceraldehyde-3-phosphate dehydrogenase gene expression assay
Total RNA was extracted with the RNeasy Midi kit (Catalogue no. 75142) from liver and kidney (Qiagen, Valencia, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase real-time PCR was performed with an RT 2 Real timet gene expression assay kit for the GAPDH (Catalogue no. QPM02946A; SuperArray Bioscience, Frederick, MD, USA). The primers were pre-tested for giving single peak in melt curve analysis. The Icycler iQ TM Real-Time Detection System (Catalogue no. 170-8740) and the expression analysis software in the instrument was used for the experiments (Bio-Rad Laboratories Inc., Hercules, CA, USA).
The Real-Time thermal cycler (Biorad Icycler iQ RealTime PCR detection system) was programmed to record the SYBR Green I signal from every reaction at annealing step of each cycle as well as melt curve analysis data. The threshold cycle for the GAPDH expression levels in different experimental groups was calculated using the software provided in the instrument.
CD4+ and CD8+ lymphocyte immunodetection
Flash-frozen sections of the liver were fixed in cold acetone for 20 min, and air-dried before washing in PBS (pH 7.4-7.6) and incubation with normal goat serum for 20 min at room temperature. Subsequently, slides were incubated with an anti-CD4 or anti-CD8 primary antibody (Pharmingen, San Diego, CA, USA) for 1 h at room temperature, followed by three washes with PBS, incubated with secondary biotinylated goat anti-rat antibody (Pharminogen, San Diego, CA, USA) for 30 min at room temperature followed by three washes with PBS. Incubation with streptavidin-conjugated alkaline phosphatase (Biogenix, Bogota, DC, USA) for 20 min at room temperature was followed by three washes with PBS preceded developing with fresh Fuchsin substrate (Biogenix) for 4-5 min to effect. Sections were counterstained with methyl green for 1 min and allowed to air dry to preserve substrate, before coating with xylene and applying a coverslip with permanent mounting medium.
